Physician profile
Joel Lee Solis
NPI 1033191424
$323,715.23
in general payments reported to CMS, 2019-2025
80 companies · $79K in 2025
The $79K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,762 · 2020: $7,205 · 2021: $21K · 2022: $23K · 2023: $93K · 2024: $93K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $178K · Travel and Lodging: $49K · Consulting Fee: $20K · Food and Beverage: $17K · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $178,267.50 |
| Travel and Lodging | $49,305.67 |
| Consulting Fee | $19,625.00 |
| Food and Beverage | $17,428.03 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $239,259.83 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $67,517.29 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Novo Nordisk INC | $2,940.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,886.48 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,412.95 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $971.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $688.70 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $633.43 | 2019-2025 | |
| Dexcom, INC. | $554.62 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amarin Pharma, INC. | $500.82 | 2019-2023 | |
| Antares Pharma, INC. | $484.86 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $468.83 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $393.01 | 2020-2024 | Livalo, Seglentis |
| Horizon Therapeutics Plc | $351.00 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $342.12 | 2020-2024 | Belsomra, Vaxneuvance, Gardasil 9 |
Show all 65 companies
15 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.